Trial Profile
A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary) ; Capecitabine; Carboplatin; Cisplatin; Everolimus; Gemcitabine; Taxanes; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 18 Jul 2016 New trial record